Figure 5.

VE-822 enhances tumor response in combination with XRT and gemcitabine in PSN-1 xenografts. (a) Growth delay experiment V: when tumors reached a volume of ∼80 mm³, treatment with VE-822 (60 mg/Kg), XRT (6 Gy) and/or gemcitabine (100 mg/Kg) was started. Subscripts in the text indicate day of treatment. Mean of tumor volume (mm³) of each treatment group (n=4–5); bars, S.D. (b) the average time (days) for tumors to reach a volume of 400 mm³ (TV400) from day 0 is shown for the different groups (means±S.D.). ns, not significant; *P<0.05; **P<0.01; ***P<0.001. (c) weight of mice throughout the experiment. (d) VE-822 does not increase normal intestinal cell radiosensitivity in vivo. Mice (n=3) were treated with VE-822 (60 mg/kg) at days 0, 2, and 4 and/or abdominal XRT (6 Gy; day 0), as indicated in the subscripts. VE-822 was administered 2 h before XRT. At day 5 mice were killed, and pieces of proximal jejunum were removed and fixed in 3% formalin/PBS for histological examinations. Frequency histogram of apoptotic cells per villus-crypt unit, based on TUNEL staining. (e and f) villus tip loss and villi length in the different groups. Data are means from six sections each obtained from different mice. Approximately 100 crypt-villus units were scored per group. (g) weight in mice treated as indicated (means±S.D.). ns, not significant; *P<0.05